Revisión
Fármacos antiangiogénicos y piel: efectos cutáneos adversos de sorafenib, sunitinib y bevacizumab
Antiangiogenic Agents and the Skin: Cutaneous Adverse Effects of Sorafenib, Sunitinib, and Bevacizumab
Servicio de Dermatología, Hospital Clínico Universitario Lozano Blesa, Zaragoza, España
Read
28041
Timeswas read the article
5636
Total PDF
22405
Total HTML
| Year/Month | Html | Total | |
|---|---|---|---|
| 2025 6 | 192 | 21 | 213 |
| 2025 5 | 556 | 56 | 612 |
| 2025 4 | 560 | 42 | 602 |
| 2025 3 | 576 | 58 | 634 |
| 2025 2 | 683 | 62 | 745 |
| 2025 1 | 376 | 36 | 412 |
| 2024 12 | 490 | 74 | 564 |
| 2024 11 | 781 | 72 | 853 |
| 2024 10 | 351 | 70 | 421 |
| 2024 9 | 308 | 53 | 361 |
| 2024 8 | 414 | 88 | 502 |
| 2024 7 | 365 | 72 | 437 |
| 2024 6 | 377 | 62 | 439 |
| 2024 5 | 398 | 69 | 467 |
| 2024 4 | 344 | 62 | 406 |
| 2024 3 | 365 | 60 | 425 |
| 2024 2 | 473 | 57 | 530 |
| 2024 1 | 502 | 59 | 561 |
| 2023 12 | 480 | 32 | 512 |
| 2023 11 | 443 | 59 | 502 |
| 2023 10 | 484 | 66 | 550 |
| 2023 9 | 521 | 48 | 569 |
| 2023 8 | 424 | 27 | 451 |
| 2023 7 | 355 | 46 | 401 |
| 2023 6 | 415 | 29 | 444 |
| 2023 5 | 381 | 31 | 412 |
| 2023 4 | 283 | 38 | 321 |
| 2023 3 | 258 | 37 | 295 |
| 2023 2 | 245 | 46 | 291 |
| 2023 1 | 204 | 23 | 227 |
| 2022 12 | 179 | 45 | 224 |
| 2022 11 | 322 | 51 | 373 |
| 2022 10 | 225 | 71 | 296 |
| 2022 9 | 233 | 69 | 302 |
| 2022 8 | 184 | 82 | 266 |
| 2022 7 | 217 | 89 | 306 |
| 2022 6 | 249 | 49 | 298 |
| 2022 5 | 262 | 107 | 369 |
| 2022 4 | 307 | 75 | 382 |
| 2022 3 | 380 | 99 | 479 |
| 2022 2 | 315 | 66 | 381 |
| 2022 1 | 350 | 91 | 441 |
| 2021 12 | 183 | 75 | 258 |
| 2021 11 | 240 | 88 | 328 |
| 2021 10 | 199 | 90 | 289 |
| 2021 9 | 134 | 76 | 210 |
| 2021 8 | 133 | 59 | 192 |
| 2021 7 | 183 | 57 | 240 |
| 2021 6 | 187 | 89 | 276 |
| 2021 5 | 180 | 66 | 246 |
| 2021 4 | 474 | 123 | 597 |
| 2021 3 | 252 | 62 | 314 |
| 2021 2 | 212 | 55 | 267 |
| 2021 1 | 151 | 62 | 213 |
| 2020 12 | 168 | 52 | 220 |
| 2020 11 | 142 | 30 | 172 |
| 2020 10 | 160 | 52 | 212 |
| 2020 9 | 172 | 35 | 207 |
| 2020 8 | 144 | 53 | 197 |
| 2020 7 | 89 | 40 | 129 |
| 2020 6 | 94 | 51 | 145 |
| 2020 5 | 104 | 76 | 180 |
| 2020 4 | 96 | 47 | 143 |
| 2020 3 | 74 | 64 | 138 |
| 2020 2 | 13 | 51 | 64 |
| 2020 1 | 6 | 41 | 47 |
| 2019 12 | 15 | 24 | 39 |
| 2019 11 | 5 | 7 | 12 |
| 2019 10 | 5 | 18 | 23 |
| 2019 9 | 0 | 15 | 15 |
| 2019 8 | 8 | 19 | 27 |
| 2019 7 | 8 | 31 | 39 |
| 2019 6 | 15 | 30 | 45 |
| 2019 5 | 11 | 50 | 61 |
| 2019 4 | 36 | 36 | 72 |
| 2019 3 | 11 | 18 | 29 |
| 2019 2 | 11 | 16 | 27 |
| 2019 1 | 38 | 6 | 44 |
| 2018 12 | 11 | 4 | 15 |
| 2018 11 | 13 | 6 | 19 |
| 2018 10 | 23 | 6 | 29 |
| 2018 9 | 5 | 1 | 6 |
| 2018 8 | 2 | 0 | 2 |
| 2018 7 | 2 | 4 | 6 |
| 2018 6 | 0 | 2 | 2 |
| 2018 5 | 0 | 6 | 6 |
| 2018 4 | 1 | 39 | 40 |
| 2018 3 | 10 | 15 | 25 |
| 2018 2 | 418 | 36 | 454 |
| 2018 1 | 187 | 30 | 217 |
| 2017 12 | 403 | 33 | 436 |
| 2017 11 | 148 | 39 | 187 |
| 2017 10 | 150 | 26 | 176 |
| 2017 9 | 127 | 29 | 156 |
| 2017 8 | 89 | 42 | 131 |
| 2017 7 | 72 | 33 | 105 |
| 2017 6 | 64 | 49 | 113 |
| 2017 5 | 62 | 45 | 107 |
| 2017 4 | 34 | 87 | 121 |
| 2017 3 | 64 | 95 | 159 |
| 2017 2 | 101 | 100 | 201 |
| 2017 1 | 104 | 67 | 171 |
| 2016 12 | 58 | 22 | 80 |
| 2016 11 | 12 | 50 | 62 |
| 2016 10 | 10 | 43 | 53 |
| 2016 9 | 2 | 52 | 54 |
| 2016 8 | 3 | 57 | 60 |
| 2016 7 | 8 | 30 | 38 |
| 2016 6 | 9 | 69 | 78 |
| 2016 5 | 6 | 7 | 13 |
| 2016 4 | 16 | 2 | 18 |
| 2016 3 | 10 | 47 | 57 |
| 2016 2 | 11 | 2 | 13 |
| 2016 1 | 6 | 4 | 10 |
| 2015 12 | 8 | 1 | 9 |
| 2015 11 | 8 | 7 | 15 |
| 2015 10 | 8 | 1 | 9 |
| 2015 9 | 10 | 4 | 14 |
| 2015 8 | 14 | 32 | 46 |
| 2015 7 | 97 | 26 | 123 |
| 2015 6 | 27 | 23 | 50 |
| 2015 5 | 13 | 24 | 37 |
| 2015 4 | 12 | 21 | 33 |
| 2015 3 | 56 | 13 | 69 |
| 2015 2 | 56 | 19 | 75 |
| 2015 1 | 39 | 15 | 54 |
| 2014 12 | 36 | 53 | 89 |
| 2014 11 | 0 | 5 | 5 |
Show all
